Infection control has historically centered on pathogen elimination, an intervention that views microorganisms as an undesirable threat to be removed, rather than as contributors to ecological balance. Previously considered a life-saving breakthrough, this model of reduction has led to the destabilization of microbial networks and is now contributing to the global increase in antimicrobial resistance (AMR). The emerging paradigm reframes infection control based on ecological therapeutics, which involves the restoration of the microbial balance rather than continuous destruction of them (Ahmed et al., 2024; Blaskovich and Cooper, 2025). In this context, the probiotics represent a next-generation antimicrobial approach designed to coexist rather than compete with microbial ecosystems. Their underlying philosophy is consistent with the One Health ethos, that life security is a matter not of fighting off microbes but of dynamism and equilibrium among the ecosystems. These concepts are further illustrated in the probiotic development pipeline, summarized in Figure 1, which delineates the Probiotic Pipeline: From Isolation to Application.

The process begins with probiotic strain isolation, where beneficial microorganisms are selected from diverse ecological niches such as soil, fermented foods, or the gut microbiome. These isolates are characterized by their safety, adaptability, and functional resilience under host and environmental conditions. Subsequently, genetic engineering enables targeted optimization of these strains. Through synthetic biology and genome editing, specific traits–such as antimicrobial peptide synthesis or resistance modulation–can be fine-tuned to enhance therapeutic efficacy while maintaining biosafety. Such precision tailoring may support the development of next-generation probiotics that align with One Health goals of minimizing resistance transfer. Within the host, probiotics exert protective effects through competitive exclusion of pathogens, occupying ecological niches and preventing opportunistic invaders from adhering to mucosal surfaces or accessing nutrients. They further strengthen this defense by producing bacteriocins–ribosomally synthesized antimicrobial peptides that selectively inhibit pathogens without disturbing commensal microbiota. Beyond pathogen control, probiotics also perform immune modulation, interacting with epithelial and immune cells to reinforce mucosal barrier integrity, stimulate antibody responses, and regulate inflammatory signaling pathways. This dual local and systemic activity promotes overall microbial–host homeostasis. Finally, the pipeline extends beyond clinical use into environmental bioremediation, where probiotic and microbial consortia degrade antibiotic residues and organic pollutants, thereby reducing the environmental resistome. These interlinked mechanisms collectively position probiotics as potential ecological stabilizers–agents that restore microbial equilibrium across human, animal, and environmental systems within the One Health continuum.

Probiotics act through several synergistic pathways in a mechanistic manner, which together may suppress pathogen growth and may inhibit the development of resistance. The competitive exclusion is one of the main strategies according to which probiotics take ecological niches previously occupied by opportunistic pathogens, depriving them of adhesion points and nutrients (Yu et al., 2025). Some of the strains encode bacteriocins, which are ribosomally encoded peptides that affect pathogenic bacteria specifically without affecting the commensal species in general. They also alter gut pH by generating organic acids or intervening quorum-sensing activation of virulence and biofilm formation, in effect silencing virulence resistance-promoting behaviors (Duche et al., 2023). Probiotics also regulate the immune system to maintain the integrity of the mucosal barriers and initiate the secretion of antimicrobial peptides locally, which form an inner system with resistance against infection.

What should, however, be noted is the fact that the majority of the existing probiotics have a transient colonization of the gastrointestinal tract. Their stay is usually temporary in nature, and their functional effects usually fade away on withdrawal. In contrast to resident commensals, a lot of probiotic strains fail to integrate and become long-term ecologically, and their utility is conditional on sustained consumption, affinity to a particular host, and environmental situation. Probiotics, therefore, can no longer be viewed as lasting replenishing agents of disturbed microbiomes, but instead ecological regulators that have the subtle effect of stabilizing microbial communities at times of weakness, like in the face of antibiotic exposure. They mainly provide resistance to selective pressure and buffering of dysbiosis instead of providing a long-term dominance of a set of microbes.

Probiotics have shown promising outcomes in controlled contexts in humans to help alleviate antibiotic-associated dysbiosis, as well as regulate the gut resistome. According to the results of metagenomic studies, probiotics can reduce the prevalence of antimicrobial resistance genes in colonization-permissive individuals, indicating that the impact of probiotics on microbial rebalancing is specific to each individual (Montassier et al., 2021). The future of microbiome biology, newer models of microbiome therapeutics merge microbiome profiling and probiotic selection, moving toward more clinically specific microbial intervention personalization (Abdul Manan, 2025). Based on targeted regulation of metabolic and inflammatory pathways, next-generation probiotics include Akkermansia muciniphila and Faecalibacterium prausnitzii, which represent a shift in strategy toward the generalized supplementation of probiotics to precision bioengineering (Abouelela and Helmy, 2024; Tiwari et al., 2024).

According to their biological potential, strict anaerobes, including Akkermansia muciniphila and Faecalibacterium prausnitzii, have considerable translational limitations. They must be grown under hypoxic bioprocessing, encapsulation-specific, and cold-chain logistics are highly controlled, making them cost-prohibitively expensive to produce, in addition to reducing scalability. These limitations have so far limited their use to highly monitored clinical or experimental trials, and they are in practice not practical as an intercessory action at the population level in most areas. Such organisms, in this case, are more about evidence-of-concept precursors of precision microbiome therapeutics aimed at not an immediate use as a population health instrument. Other more viable translational options, such as spore-forming strains, formulated mixtures of defined microbial communities, and postbiotic formulations, may provide more practical translational solutions, especially in low-resource and large-scale agriculture (Abouelela and Helmy, 2024; Tiwari et al., 2024).

Alternatives to antibiotic growth promoters (AGPs) in animal health have been investigated using probiotics, mainly by lightening the burden of pathogens and enhancing the integrity of the gut. Nonetheless, in contrast to antimicrobials, the growth-promoting effects that AGPs have historically played in all of the production systems are not always replicated with probiotics. They are effective depending on the host species, husbandry conditions, diet, and formulation, and trade-offs in economics have continued as a major obstacle to implementation. Based on this, probiotics cannot be considered as direct functional substitutes of AGPs; rather, they are risk-reducing and resilience-promoting solutions, which facilitate a slow transformation in the habit of using antimicrobials in the context of stewardship. The experimental models have also shown that probiotic supplementation has been associated with decreased pathogen load and enhanced the morphology of the gut, and little selection pressure is induced by the use of antimicrobials. Nevertheless, the commercial preparations contain some remnants of transferable resistance genes, such as tetS and APH (3)-Ia, which highlights the significance of rigorous genomic safety assays (Kerek et al., 2024). Claiming that probiotic-based sanitation systems have proven to be ecologically promising, long-term hospital trials using Bacillus subtilis and B. velezensis consortia have demonstrated genomic stability under studied conditions, with neither virulence nor resistance determinants, making them environmentally safe and capable of minimizing pathogen bioburden (Bini et al., 2025). These results corroborate the point that probiotic interventions can act safely within One Health realms when they are duly validated.

Beyond host-associated benefits, probiotics also contribute to environmental stability, particularly through mechanisms that support bioremediation. Such systems can also cause the environmental resistome to become disconnected by surpassing resistant bacteria and restricting the spread of antibiotic resistance genes (ARGs) horizontally (Klümper et al., 2025). Incorporation of such microbial solutions into wastewater treatment and runoff control of agricultural enterprises would help to significantly reduce the spread of resistance on the ecosystem level.

Innovation leads to frontiers that create probiotics in programmable therapeutics and not just in natural systems. Synthetic biology is being used to create engineered probiotics, which can be designed to release particular molecules or combat pathogens locally (Zhang et al., 2025). CRISPR-based reagents provide a chance to specifically remove resistance plasmids, providing a nice biotechnological breadth of path to reverse resistance dissemination (Liu et al., 2023; Rahmati et al., 2025). Similar antimicrobial activities are supported by parallel improvements in non-viable microbial components for enhancing microbial health, known as postbiotics, which do not provoke regulatory or stability complications associated with live cultures (Amobonye et al., 2025; Calvanese et al., 2025). Together, these advancements indicate the coming together of the science of microbiomes, genomics, and biotechnology into one therapeutic frontier.

The next stage of infection management may involve not only the development of the biochemical arms race but also reprogramming ecological resilience. Precursors and derivatives of probiotics relate to such transformation: adaptive, sustainable, and integrative agents, and they work along the animal-environment-human continuum. Representative probiotic strains validated for AMR mitigation across human, animal, and environmental contexts are summarized in Table 1. Probiotic-based therapeutics can reimagine the role of combating AMR not by dominance, but by balance, switching to a microbial coexistence model. Such ecosystem-level validation demands harmonized policy frameworks that connect laboratory efficacy with field sustainability–central to the One Health vision of balanced microbial governance.

The strongest evidence of probiotic interventions in AMR reduction is best seen in situations where antibiotics interfere with the homeostasis of microbes and not in the reversal of those at the population level. The meta-analyses and controlled studies all indicate that probiotics prevent antibiotic-associated dysbiosis, prevent the overgrowth of pathogens and alter the resistome composition in a host- and antibiotic-specific way. Notably, it is the role of decreased selective pressure, competition to occupy a niche, and stabilization of commensal communities that mediate these effects, as opposed to direct eradication of resistance determinants. In that regard, probiotics have to be discussed as pressure-reducing and resilience-building mechanisms which supplement, yet do not substitute antimicrobial interventions in the framework of integrated stewardship approaches.

Beyond biology, AMR persistence reveals a cultural dimension, where misinformation, policy gaps, and behavioral inertia intersect. Antimicrobial resistance (AMR) has often been discussed as a pharmacological crisis caused by microbial evolution and clinical abuse, but its persistence also reflects underlying cultural and behavioral challenges. Nevertheless, despite all the campaigns, the global societies perceive the use of antibiotics in a biased manner, where instead of looking at the systems, microbiomes, and ecosystems, they look at medications and pathogens. Such narrowing down keeps reactionary policies and impedes the change of behavior. Research shows that the incorrect beliefs are still present even in developed countries, where most people still hold the belief that resistance develops within the human body or that antibiotics help them overcome viral diseases (Molan et al., 2025). These misconceptions continue to perpetuate self-prescription, lack of compliance, and abuse across all markets. An overview of the current limitations in antimicrobial resistance management, along with emerging solutions based on probiotics, microbiome literacy, and One Health–aligned surveillance, is presented in Table 2.

To make microbiome literacy operational, principles of microbial ecology should be incorporated into existing public health and governance structures rather than creating parallel educational systems. Effective implementation channels involve antimicrobial stewardship programs, school and medical training, in veterinary extension programs aiming to reduce growth promoters in antimicrobials, and citizen-science engagement practices that involve communities in microbiome awareness. These methods have been linked to a higher rate of antibiotic adherence, a decreased level of self-medication, and an enhanced acceptance of non-antibiotic measures. Microbiome literacy, by providing abstract microbiome notions into behavioral norms, works effectively as a pragmatic upstream intervention by strengthening antimicrobial stewardship along One Health sectors.

However, recent articles have termed AMR a Silent Pandemic, where ignorance, as opposed to biology itself, promotes its transmission (Ahmed et al., 2024). These gaps are not limited to the general population; policymakers, clinicians, and farmers also demonstrate significant awareness deficits present in policymakers, clinicians, and farmers, and they fragment accountability along the One Health axis (Ahmed, 2025). This cycle needs to be addressed by turning awareness into microbiome literacy, or a mutual perception of dependence and ecological strength on microbes (Altevogt et al., 2025).

This shift is testified by educational innovations. The Microbiome and Health web-based course also helped enhance a deeper understanding of microbial ecology and sustainability in different learners (Schweitzer et al., 2025). Microbial literacy can be normalized through embedding this kind of content into school curricula, veterinary education, and health education to produce individuals who understand microbial coexistence rather than viewing microbes as adversaries.

The programs of citizen science have even more democratized the study of the microbiome. Citizen science platforms now allow communities to study their gut microbiomes, leading to transparency and inclusion, which are consistent with cross-sectoral frameworks of surveillance (Lappan et al., 2024; Vallejo-Espín et al., 2025). Social media further serves as an amplifier: campaigns and storytelling based on inclusive messages, like the one claiming that microbiological science is translated into accessible public messages, which is the message that reads like protect your microbes, protect your future.

Yet, literacy should be involved in systemic reform. One Health stewardship model stresses that education alone is insufficient without policy frameworks that reinforce responsible antimicrobial usage (Altevogt et al., 2025). To link microbial ecology to sustainability, environmental education must focus on ARG mobility by means of soil and water systems (Klümper et al., 2025).

Microbiome literacy is a behavioral intervention when supported through education, governance, and culture. Well-informed communities are more compliant with stewardship interventions, less prone to misuse of antibiotics, and more tolerant of alternative forms of treatment like probiotics. Agricultural systems also have awareness that is connected to less use of antimicrobial growth promoters and more that will open to probiotics feed intervention (Kerek et al., 2024). This cultural shift is both behavioral and ecological, moving human activity toward coexistence rather than conflict with microbes.

One Health Microbiome Intelligence Framework (OH-MIF) is suggested as a conceptual surveillance framework intertwining heterogeneous data pertinent to AMR dynamics, as opposed to a technological platform that can be deployed. The core data inputs are clinical information (antimicrobial prescriptions, resistance profile, patient microbiome profile), genomic and metagenomic information (ARG abundance, mobility marker, resistome composition), agricultural information (antimicrobial and probiotic use in livestock systems), and environmental information (wastewater, soil, and surface water resistome). In this context, AI-driven analytics can be used to detect patterns, stratify ecological risk, and create advanced warning signals of the development of resistance instead of discussing clinical or regulatory choices. The most common ones are standardizing data used in sectors, the capability to enable any one of the surveillance systems to work together, anonymity to balance privacy, and compliance with governance among the national and international agencies.

Global AMR surveillance remains fragmented, with the clinical data mostly prevailing, with less integration of the agricultural, environmental, or probiotic knowledge. Existing systems like the GLASS (Global Antimicrobial Resistance and Use Surveillance System) of WHO or other sets of sector surveillance provided by FAO (Food and Agriculture Organization) and OIE (now termed as World Organization for Animal Health) rarely incorporate probiotic performance or microbiome homeostasis indicators (Lappan et al., 2024; Vallejo-Espín et al., 2025). To address this gap, a One Health Microbiome Intelligence Framework (OH-MIF) is proposed, which is a unified system integrating genomic, clinical, agricultural, and environmental microbiome datasets for AMR management. However, implementing such a system requires addressing challenges such as data standardization across countries, interoperability of heterogeneous databases, data privacy protections, and the computational resources needed for large-scale microbiome analytics.

This model would operate with the help of cloud-based databases that can track the safety of probiotic strains, ARG (Antibiotic Resistance Gene) transmission, and ecological performance (Kerek et al., 2024; Zavišić et al., 2023). AI-driven correlation mapping would be able to connect the usage patterns of probiotics and the local trends of AMR (Abdul Manan, 2025), whereas integrated metagenomic pipelines would help track the flow of ARG through the hospital, farm, and wastewater systems (Altevogt et al., 2025; Klümper et al., 2025).

Policy reform is necessary to supplement data integration. A Global Request for Competitive Standing (RCS) system for probiotics, such as Genomic validation, AMR risk profiling, and biosafety certification, would provide the ecological stability and avoid the spread of resistance unintentionally (Kerek et al., 2024; Zavišić et al., 2023). These standards would be institutionalized through intersectoral cooperation of ministries, agricultural boards, and environmental agencies in the process of national AMR action plans.

The OH-MIF is designed to integrate currently isolated biotherapeutic data streams into a coherent AMR mitigation infrastructure. It may enable monitoring microbial dynamics across systems in real-time through standardized data streams, continuous feedback control, and AI-enhanced analytics. This model would harmonize surveillance as well as support adaptive policymaking. The model would strengthen the connection between microbial ecology and the ultimate outcomes of public health.

Eventually, the future requires probiotics and AMR screening not to develop side by side but synchronously. Coordinated microbiome intelligence can help transform fragmented surveillance data into coherent, actionable insights that support microbial coexistence. Institutionalized information-sharing and environmental integration may enable a shift from reactive response toward anticipatory AMR management and strengthened microbial resilience. The operational structure of this model is depicted in Figure 2, highlighting the integration of clinical, agricultural, and environmental datasets into a unified intelligence framework.

The OH-MIF is set to support the current AMR monitoring programs, not to dissolve them, e.g., the WHO Global Antimicrobial Resistance and Use Surveillance System (GLASS) and FAO-WHO-WOAH Tripartite frameworks. Although the existing systems are mainly aimed at monitoring the prevalence of resistance and antimicrobial usage, OH-MIF builds on the same platform by including the measures of microbiome stability, probiotic safety endorsement, and ARG motility between environmental reservoirs. Placing OH-MIF as part of an established governance framework can increase policy relevance and help become part of the national AMR action plans without further redundancies in surveillance.